Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02960399 · ClinicalTrials.gov registry record · NA

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

A NA study, sponsored by University of South Florida.

Terminated
Registry status
NA
Development phase
2
Enrollment target

NCT02960399: Clinical Trial NA study, sponsored by University of South Florida.

NCT02960399 is a NA study that was terminated before completion, run by University of South Florida. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02960399, a NA study, was terminated before completion, sponsored by University of South Florida.

TERMINATED
Registry status
NA
Development phase
2 participants
Enrollment target

Study Summary

Recommendations concerning the administration of Zostavax® in patients with antibody deficiency are unclear. The investigators plan to assess the immunogenicity and safety of Zostavax® in patients with antibody deficiency as compared with healthy volunteers.

Primary Outcome

Determine in vitro lymphocyte proliferation as counts per minute after stimulation of cells with varicella zoster antigen at time points preceding and following vaccination with Zostavax. Blood samples will be obtained prior to administering the Zostavax® vaccine and post-vaccination at 4 weeks, 3 months, and 6 months.

Interventions

  • BIOLOGICAL Zostavax®

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2015-12
Est. Completion 2017-12
Phase NA
University of South Florida

252 total trials

Why NCT02960399 stopped before completion

NCT02960399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 1 intervention - of which Zostavax® is the first listed.

NCT02960399 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02960399 about?

NCT02960399 is a clinical study titled "Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older". Recommendations concerning the administration of Zostavax® in patients with antibody deficiency are unclear. The investigators plan to assess the immunogenicity and safety of Zostavax® in patients with antibody deficiency as compared with healthy volunteers.

What is the current status of trial NCT02960399?

This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2015-12. Estimated completion is 2017-12.

What interventions are being tested in trial NCT02960399?

The interventions under investigation include: Zostavax® (BIOLOGICAL).

Who is sponsoring clinical trial NCT02960399?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02960399's enrollment target sits among peer trials

2 1997th of 2000 the lowest of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02960399, the US trial registry maintained by the National Library of Medicine. NCT02960399 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.